res
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company and IRBM, a drug discovery company, have entered a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.
IRBM is a drug discovery CRO with expertise ranging from target validation and hit finding to preclinical candidate nomination across various therapeutic areas, including oncology, infectious diseases and neuroscience.
Carlo Toniatti, MD, PhD, CSO, IRBM, said: “With the integration of CRISPR/Cas9 gene editing technology we are increasing our capability to identify and validate potential drug targets, to generate more predictive pre-clinical models and to elucidate the mechanisms of action of novel therapeutics.”
ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programmes.
Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 usage in all cells, including eukaryotic and prokaryotic cells such as mammalian cells, bacteria, archaea, yeasts, algae and insects. ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.
